Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gotta love Tuesday Koosday Newsday! Looking forward to the rest of the week and into next month!
$ RGBP $
Oh, yeah I was referring to the original divvy that became RGBP.
So what's the strategy/motivation from RGBP's prospective? Are they looking to initiate a substantial degree of buying on the stock? I'm not skeptical, just curious as to the purpose of an additional divvy after having received the RGBP shares last year.
$ RGBP BMSN $
Yes, thanks for drawing attention to this. IMO that really should have been the focus of the PR, then as a bonus they could still throw in the detail about Flexus as a side note. For dCellVax, we should anticipate future news when the finalized comments have been sent, or about the FDA's response to them (i.e., they could initiate a second round of questioning).
$ RGBP $
So glad to have seen this! Thanks for sharing GM!
$ RGBP $
Nice find GM, we were just talking about that patent! I like how they make it sound like reporters interviewed the patent:
Great buys, raising bid; 0.1328(BID) x 0.1329(ASK)
RGBP patent published Feb 5, 2015 - CELLS, COMPOSITIONS, AND TREATMENT METHODS FOR STIMULATION OF HEMATOPOIESIS
D.Koos & T.E.Ichim
http://www.freepatentsonline.com/y2015/0037303.html
This patent covers the methodology of HemaXellerate I and even details the proposed clinical trial protocol!
$$ RGBP BMSN $$
Hey thanks! Yeah that's right; quietly waiting for something noteworthy to happen - and it has! I'm interested to see if a PR will follow soon.
$ RGBP $
Finally, they're raising the bid!
$ RGBP $
Thanks for finding and sharing this info NEW4THIS; reliable and relevant as always! I wouldn't be surprised to see a PR announcement about this CFO appointment soon, and it seems like a good sign of things to come.
Cheers
RGBP
Thanks for sharing! There's some good info here:
Looking good; about time we broke 0.15!
$ RGBP $
Yeah me too. Still, I've seen conferences that are surprisingly more successful in their execution of the poster session than the oral. The thing is, even with a coveted oral presentation, you can run into situations where there's literally only 5-10 people in the room, depending on the time and what else is being presented in another room at the same time. At least the poster session guarantees some foot traffic and more personal/informal interactions and networking.
That's correct, and a poster is referred to in the academic community as a "Poster Presentation" as opposed to an "Oral Presentation". She will be standing there alongside the poster, "presenting" it and taking questions/discussion about it. It's more of an open format than an oral presentation.
$ RGBP $
Yes exactly, thank you! And it's a great networking opportunity; you never know!
If you need clarification, on the conference website click "Search by Day" to see how it's organized. You'll notice that Saturday from 5:30PM - 7:30PM is referred to as "Poster Session I", and it has its own welcome reception in the Poster Halls (Level 1 Moscone). Christine Ichim's category is the first one on that list, #101.
IMPORTANT - It seems that Christine Ichim's presentation at the conference this weekend is a poster, rather than oral (see link below). For those not familiar with this format, this is where you affix a poster detailing your research to a backing board in an expo room with other researchers and posters organized in rows. People walk around, read your poster, and engage in conversation with the 'presenter' about it. It is a very good networking tool, but it is not the same as speaking from a podium to a room full of attentive people. For this reason, I don't expect any "announcements" to be made regarding FDA approval, as has been speculated. Nevertheless, that doesn't exclude the possibility that we could see an update PR with the coming weeks!
For what it's worth, I'm glad to see their participation in events like this, as it'll help to get the name around and to have qualified people like Christine Ichim representing the company.
https://ash.confex.com/ash/2014/webprogram/Paper74085.html
(Details: notice how it says "Poster I" for the session name, and that the duration is 2 hours in the evening; as is typical for poster sessions)
$$ RGBP BMSN $$
It's great to see that Christine Ichim's work is moving forward through the RGBP pipeline. This is a great complement to the existing roster of HemaXellerate and dCellVax. Looking like a good day here as well; good times coming!
$$ RGBP BMSN $$
Fantastic, the wheels are in motion!
$$ RGBP BMSN $$
No I don't, sorry. Mine isn't giving me any problems trading RGBP right now, so it must be an iTrade thing.
Best of luck!
Bear in mind that the recent submission for additional info is actually an initiation of pre-clinical work to be conducted in a GLP-certified laboratory (see quote below for reference). This could take several months for them to complete. That being said, dCellVax has the opportunity to surpass HemaXellerate in the FDA process, provided the dCellVax IND is airtight. There's a good chance it is, given Dr. Min's involvement and the experiments in animal models and human cells that have already been conducted.
SUMMARY OF DCELLVAX PROGRESS (UPDATED OCT 2014):
Feb 26, 2013 - BMSN announce Letter of Intent (LOI) to acquire WP Min cancer gene-silencing intellectual property.
http://ih.advfn.com/p.php?pid=nmona&article=56463068
Apr 4, 2013 - Update about pre-clinical and clinical programs; planned IND submission for Q4 2013.
http://ih.advfn.com/p.php?pid=nmona&article=57035344
May 6, 2013 - Regen officially acquires WP Min cancer gene-silencing therapy patent; will focus efforts on breast cancer.
http://ih.advfn.com/p.php?pid=nmona&article=57439657
Aug 8, 2013 - Regen licenses cancer gene-silencing therapy from Benitec BioPharma; demonstrates its action on IDO in dendritic cells.
http://ih.advfn.com/p.php?pid=nmona&article=58739425
Aug 16, 2013 - Conducting toxicity experiments using WP Min and Benitec technologies; reiterates planned submission of IND by Q4 2013.
http://ih.advfn.com/p.php?pid=nmona&article=58853168
Sept 17, 2013 - BMSN recruit Dr. David Suhy to Regen advisory board; his experience in RNAi is useful for Regen's cancer therapy.
http://ih.advfn.com/p.php?pid=nmona&article=59244933
Sept 25, 2013 - Announcement of "dCellVax" breast cancer immunotherapeutic product; outline further 8 months of milestones.
http://ih.advfn.com/p.php?pid=nmona&article=59354656
Jun 11, 2014 - Announce research paper on the use of gene-silencing in heart transplants, showing multiple applications of dCellVax technology; dCellVax IND planned for August 2014.
http://ih.advfn.com/p.php?pid=nmona&article=62529632
Aug 1, 2014 - Update on dCellVax progress; Regen successfully achieves silencing of the IDO gene in human dendritic cells ahead of expected IND submission.
http://www.marketwatch.com/story/regen-biopharma-provides-update-on-dcellvax-breast-cancer-immunotherapy-2014-08-01
Sept 16, 2014 - Regen announce patent filing for novel means of cancer immunotherapy; basis of dCellVax.
http://www.marketwatch.com/story/regen-biopharma-files-patent-application-on-new-therapy-that-uses-the-innate-immune-system-to-kill-cancer-2014-09-16
Oct 1, 2014 - Regen completes preclinical experiments, begins preparation of IND application.
http://www.marketwired.com/press-release/regen-biopharma-completes-preclinical-experiments-dcellvax-breast-cancer-immune-therapy-otcbb-rgbp-1952694.htm
Oct 8, 2014 - Regen files dCellVax IND.
http://www.marketwired.com/press-release/regen-biopharma-inc-files-ind-application-with-fda-dcellvax-breast-cancer-immune-therapy-otcbb-rgbp-1955886.htm
** All dates listed above refer to the date of the linked PR **
For further Regen BioPharma timelines, please see my post on HemaXellerate I progress: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106944954
$$ RGBP BMSN $$
Showing 139,539 for me on OTC and iHub currently.
Wow dCellVax IND filing! We knew this day would be soon, so why not today?! Definitely pleased with the company's communication since RGBP has begun to trade; what's it been now, 5 PRs in about a month!
Was expecting more of a PPS reaction off this news, but we'll wait and see, could be a slow steady build...
$$ RGBP BMSN $$
Well said PoPo. I'm guessing the next HemaXellerate PR will be them having heard back from the FDA and getting the go-ahead for the proposed GLP-certified safety study (or, addressing revisions to the proposition). Hopefully at that time they'll also provide a revised timeline for when those experiments might be completed, but realistically we'll have to expect that it could be several months to finish the new study.
With the typical 30-day turn around, I'd be on the lookout for this by early November. In the meantime, they'll have time to prep the dCellVax IND!
$$ RGBP BMSN $$
SUMMARY OF HEMAXELLERATE I PROGRESS (UPDATED OCT 2014):
Jan 24, 2013 - Pre-clinical proof of concept and plan to file IND.
http://ih.advfn.com/p.php?pid=nmona&article=55986712
Feb 5, 2013 - Announcement that IND was filed.
http://ih.advfn.com/p.php?pid=nmona&article=56150687
Mar 18, 2013 - Regen receives IND# from FDA.
http://ih.advfn.com/p.php?pid=nmona&article=56788567
Apr 4, 2013 - FDA will send a letter outlining items which must be addressed prior to initiating clinical trials.
http://ih.advfn.com/p.php?pid=nmona&article=57035344
Jun 6, 2013 - Regen responds to FDA questions (including new data).
http://ih.advfn.com/p.php?pid=nmona&article=57897013
Jul 31, 2013 - Regen in second round of discussion with FDA on a new set of FDA comments.
http://ih.advfn.com/p.php?pid=nmona&article=58628844
Sept 26, 2013 - Agreement for pre-clinical animal trials with WP Min to address FDA comments.
http://ih.advfn.com/p.php?pid=nmona&article=59372541
Oct 31, 2013 - Cook General Biotechnology to continue producing clinical grade HemaXellerate I for pre-clinial and clinical studies.
http://ih.advfn.com/p.php?pid=nmona&article=59847939
Dec 11, 2013 - Update on WP Min work regarding pre-clinical animal studies
http://ih.advfn.com/p.php?pid=nmona&article=60352616
May 12, 2014 - FDA accepted the clinical protocol and the product manufacturing information; clarification on animal safety studies was requested.
http://ih.advfn.com/p.php?pid=nmona&article=62167863
Sept 10, 2014 - Regen to submit additional safety data from a GLP-certified lab prior to initiating clinical trials.
http://www.marketwired.com/press-release/regen-biopharma-provides-update-on-hemaxellerate-ind-progress-after-conference-call-otcbb-rgbp-1945965.htm
Oct 6, 2014 - Experimental protocol submitted to FDA regarding proposed pre-clinical experiments; follow-up from previous PR.
http://www.marketwired.com/press-release/regen-biopharma-submits-experimental-protocol-fda-hemaxellerate-aplastic-anemia-trial-otcbb-rgbp-1954889.htm
** All dates listed above refer to the date of the linked PR **
For further Regen BioPharma timelines, please see my post on dCellVax progress:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106823399
Yeah I certainly wouldn't be surprised to see it at least by the end of this month. The story has been building over the last few months; successful human cell silencing, patent filing - looks like they're in much better shape with this one than HemaXellerate was when it was submitted.
SUMMARY OF DCELLVAX PROGRESS (UPDATED OCT 2014):
Feb 26, 2013 - BMSN announce Letter of Intent (LOI) to acquire WP Min cancer gene-silencing intellectual property.
http://ih.advfn.com/p.php?pid=nmona&article=56463068
Apr 4, 2013 - Update about pre-clinical and clinical programs; planned IND submission for Q4 2013.
http://ih.advfn.com/p.php?pid=nmona&article=57035344
May 6, 2013 - Regen officially acquires WP Min cancer gene-silencing therapy patent; will focus efforts on breast cancer.
http://ih.advfn.com/p.php?pid=nmona&article=57439657
Aug 8, 2013 - Regen licenses cancer gene-silencing therapy from Benitec BioPharma; demonstrates its action on IDO in dendritic cells.
http://ih.advfn.com/p.php?pid=nmona&article=58739425
Aug 16, 2013 - Conducting toxicity experiments using WP Min and Benitec technologies; reiterates planned submission of IND by Q4 2013.
http://ih.advfn.com/p.php?pid=nmona&article=58853168
Sept 17, 2013 - BMSN recruit Dr. David Suhy to Regen advisory board; his experience in RNAi is useful for Regen's cancer therapy.
http://ih.advfn.com/p.php?pid=nmona&article=59244933
Sept 25, 2013 - Announcement of "dCellVax" breast cancer immunotherapeutic product; outline further 8 months of milestones.
http://ih.advfn.com/p.php?pid=nmona&article=59354656
Jun 11, 2014 - Announce research paper on the use of gene-silencing in heart transplants, showing multiple applications of dCellVax technology; dCellVax IND planned for August 2014.
http://ih.advfn.com/p.php?pid=nmona&article=62529632
Aug 1, 2014 - Update on dCellVax progress; Regen successfully achieves silencing of the IDO gene in human dendritic cells ahead of expected IND submission.
http://www.marketwatch.com/story/regen-biopharma-provides-update-on-dcellvax-breast-cancer-immunotherapy-2014-08-01
Sept 16, 2014 - Regen announce patent filing for novel means of cancer immunotherapy; basis of dCellVax.
http://www.marketwatch.com/story/regen-biopharma-files-patent-application-on-new-therapy-that-uses-the-innate-immune-system-to-kill-cancer-2014-09-16
Oct 1, 2014 - Regen completes preclinical experiments, begins preparation of IND application.
http://www.marketwired.com/press-release/regen-biopharma-completes-preclinical-experiments-dcellvax-breast-cancer-immune-therapy-otcbb-rgbp-1952694.htm
** All dates listed above refer to the date of the linked PR **
For further Regen BioPharma timelines, please see my post on HemaXellerate I progress: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106166628
$$ RGBP BMSN $$
Yes, "subsequent to the date of completion", but it doesn't mean the company can't just have them on hand for when the time comes. I'm not even saying that I agree with the fact that they're milestone or otherwise, but there's more than one way to look at things.
$ RGBP $
SUMMARY OF DCELLVAX PROGRESS (UPDATED SEPT 2014):
Feb 26, 2013 - BMSN announce Letter of Intent (LOI) to acquire WP Min cancer gene-silencing intellectual property.
http://ih.advfn.com/p.php?pid=nmona&article=56463068
Apr 4, 2013 - Update about pre-clinical and clinical programs; planned IND submission for Q4 2013.
http://ih.advfn.com/p.php?pid=nmona&article=57035344
May 6, 2013 - Regen officially acquires WP Min cancer gene-silencing therapy patent; will focus efforts on breast cancer.
http://ih.advfn.com/p.php?pid=nmona&article=57439657
Aug 8, 2013 - Regen licenses cancer gene-silencing therapy from Benitec BioPharma; demonstrates its action on IDO in dendritic cells.
http://ih.advfn.com/p.php?pid=nmona&article=58739425
Aug 16, 2013 - Conducting toxicity experiments using WP Min and Benitec technologies; reiterates planned submission of IND by Q4 2013.
http://ih.advfn.com/p.php?pid=nmona&article=58853168
Sept 17, 2013 - BMSN recruit Dr. David Suhy to Regen advisory board; his experience in RNAi is useful for Regen's cancer therapy.
http://ih.advfn.com/p.php?pid=nmona&article=59244933
Sept 25, 2013 - Announcement of "dCellVax" breast cancer immunotherapeutic product; outline further 8 months of milestones.
http://ih.advfn.com/p.php?pid=nmona&article=59354656
Jun 11, 2014 - Announce research paper on the use of gene-silencing in heart transplants, showing multiple applications of dCellVax technology; dCellVax IND planned for August 2014.
http://ih.advfn.com/p.php?pid=nmona&article=62529632
Aug 1, 2014 - Update on dCellVax progress; Regen successfully achieves silencing of the IDO gene in human dendritic cells ahead of expected IND submission.
http://www.marketwatch.com/story/regen-biopharma-provides-update-on-dcellvax-breast-cancer-immunotherapy-2014-08-01
Sept 16, 2014 - Regen announce patent filing for novel means of cancer immunotherapy; basis of dCellVax.
http://www.marketwatch.com/story/regen-biopharma-files-patent-application-on-new-therapy-that-uses-the-innate-immune-system-to-kill-cancer-2014-09-16
** All dates listed above refer to the date of the linked PR **
For further Regen BioPharma timelines, please see my post on HemaXellerate I progress: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106166628
$$ RGBP BMSN $$
HUGE NEWS IMO! One step closer to dCellVax IND!
$ RGBP $
That's true. The majority of their previous updates have had dates and expected timelines included, which is why I found it strange that the recent PR did not. For now, I'll entertain your theory Traz and weather the storm! In the meantime things should get interesting if we see the anticipated dCellVax IND submission.
$$ RGBP / BMSN $$
I agree Pete, yesterday's volume was only ~5% of the tradeable O/S and today is an even smaller fraction so far. I think some people can't stomach waiting another 6 months (or whatever our new time frame may be!), and that's a fair opinion to have, but the news in no way hints that approval won't happen; in fact, it's an even surer sign that approval in fact WILL occur, just at a later date than most are comfortable with. I feel fine with RGBP and BMSN as a long play, as much as it pains me to view the short term charts right now.
SUMMARY OF HEMAXELLERATE I PROGRESS (UPDATED SEPT 2014):
Jan 24, 2013 - Pre-clinical proof of concept and plan to file IND.
http://ih.advfn.com/p.php?pid=nmona&article=55986712
Feb 5, 2013 - Announcement that IND was filed.
http://ih.advfn.com/p.php?pid=nmona&article=56150687
Mar 18, 2013 - Regen receives IND# from FDA.
http://ih.advfn.com/p.php?pid=nmona&article=56788567
Apr 4, 2013 - FDA will send a letter outlining items which must be addressed prior to initiating clinical trials.
http://ih.advfn.com/p.php?pid=nmona&article=57035344
Jun 6, 2013 - Regen responds to FDA questions (including new data).
http://ih.advfn.com/p.php?pid=nmona&article=57897013
Jul 31, 2013 - Regen in second round of discussion with FDA on a new set of FDA comments.
http://ih.advfn.com/p.php?pid=nmona&article=58628844
Sept 26, 2013 - Agreement for pre-clinical animal trials with WP Min to address FDA comments.
http://ih.advfn.com/p.php?pid=nmona&article=59372541
Oct 31, 2013 - Cook General Biotechnology to continue producing clinical grade HemaXellerate I for pre-clinial and clinical studies.
http://ih.advfn.com/p.php?pid=nmona&article=59847939
Dec 11, 2013 - Update on WP Min work regarding pre-clinical animal studies
http://ih.advfn.com/p.php?pid=nmona&article=60352616
May 12, 2014 - FDA accepted the clinical protocol and the product manufacturing information; clarification on animal safety studies was requested.
http://ih.advfn.com/p.php?pid=nmona&article=62167863
Sept 10, 2014 - Regen to submit additional safety data from a GLP certified lab prior to initiating clinical trials.
http://www.marketwired.com/press-release/regen-biopharma-provides-update-on-hemaxellerate-ind-progress-after-conference-call-otcbb-rgbp-1945965.htm
** All dates listed above refer to the date of the linked PR **
For further Regen BioPharma timelines, please see my post on dCellVax progress:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=104902493
Thanks for the insight, let's hope that "telephonic" call was months ago (around the end of the previous 30-day wait time) and the GLP lab safety study is well underway. As you said, it's not denial, so the selling must be due to disappointed/impatient hands (not that there's anything wrong with that!). Only strategy left is to hold and watch RGBP and BMSN make recoveries from their currently oversold state as further news comes in.
Sent from my mobile
Wow Crabby, I missed this entire trading day and it looks like it was a strange one! So I see we've got our first official RGBP PR as an update for HemaXellerate, but it's a little ambiguous as to the projected timeline, no? I'm also confused by the large drop in price here and at BMSN. Is the consensus here that a lot of people were not pleased because the PR did not state FDA approval? It doesn't look like any plans have been derailed, but it presents a possible delay. Maybe dCellVax IND in the meantime?
Also, thanks for sharing your story, best of luck to you and your family! Cheers!
Fantastic! Falling into place exactly as you reported in yesterday's DD. Thanks again!
$ RGBP $
Lol exactly! And now we're seeing development of the pinky finger, transitiong the chart into the ever-popular "Rock On!" formation. Good things on the way indeed.
$ RGBP $
Bid at 0.42 now, ready for another move up!
$ RGBP $